Search

Displaying results 6721 - 6730 of 9714 in total
  1. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity.

  2. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [A3197] Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABA<sub>A</sub> receptors to enhance their inhibitory effects … [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors.

    Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
  3. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...

  4. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  5. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.

    Categories: Venombin A
  6. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    As a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.

  7. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.

  8. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  9. Drug

    16-Bromoepiandrosterone

    go.drugbank.com/drugs/DB05107
    Investigational

    16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.

  10. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index